Anti-cytokine autoantibodies: Epiphenomenon or critical modulators of cytokine action

Meide, P. H. Van Der; Schellekens, Huub

doi:10.1007/978-94-011-5664-6_6

Cited by 2 publications

(1 citation statement)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sporadic autoantibodies to IFN‐α 8 and a number of other cytokines, including IFN‐γ, 9 IL‐2, 10 IL‐6, 12 IL‐8, IL‐10, 15 and tumour necrosis factor‐α (TNF‐α), 16 have been detected in patients with various autoimmune, malignant, or infectious disorders. These, and autoantibodies to IL‐1α and granulocyte–macrophage colony‐stimulating factor (GM‐CSF), have also been sporadically found in apparently healthy individuals 17 –23 . While many of them can neutralize their respective cytokine in culture, their in vivo effects and clinical significance remain enigmatic.…”

Section: Introductionmentioning

confidence: 99%

Spontaneously occurring neutralizing antibodies against granulocyte–macrophage colony‐stimulating factor in patients with autoimmune disease

et al. 1999

View full text Add to dashboard Cite

There is increasing evidence that spontaneous anticytokine autoantibodies are associated with chronic infections and autoimmune diseases. We report the sporadic occurrence in autoimmune diseases of such autoantibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine involved in inflammation and the regulation of proliferation, differentiation and function of granulocytic and monocytic cell lineages. In 41 of 425 patients tested, we found low to moderate levels of autoantibodies binding to GM-CSF in serum or plasma. These were most prevalent in patients with myasthenia gravis (MG). However, neutralizing autoantibodies against GM-CSF were very rare, being found in only three patients. Two had autoimmune MG, one with thymoma (Patient A) and the other (Patient B) with 'seronegative' MG, i.e. without the antiacetylcholine receptor autoantibodies characteristic of most MG patients, and a third (Patient D) had multiple sclerosis. Only very limited amounts of Patient A and Patient D serum/plasma were available for analysis and therefore further studies were carried out on the more plentiful samples from Patient B. The anti-GM-CSF autoantibodies of Patient B were predominantly polyclonal immunoglobulin G and strongly neutralized recombinant human (rh) GM-CSF derived from different expression systems. They had similar immunological and immunochemical characteristics to anti-GM-CSF antibodies that developed in immunocompetent colorectal carcinoma patients following (rh)GM-CSF therapy. In serial samples from Patient B, the anti-GM-CSF autoantibodies were undetectable from diagnosis at age 8 years until at least age 13, but then developed spontaneously during (temporary) withdrawal of immunosuppressive treatment. Their neutralizing activity has persisted since their first detection at age 15 years 1 month, and was at its highest level recently at age 17 years 7 months. There was no obvious association with other autoimmune phenomena, nor were any haematological deficiencies overtly manifested, suggesting that any loss of GM-CSF function may have been compensated for by other cytokines.

show abstract